Patent ID: 6919457

Claim:
A medicament according to formula (I) wherein: n is 1, 2, 3 or 4; R 1 is selected from (a) an optionally substituted straight chain or branched chain C 1-6 alkyl group, (b) an optionally substituted straight chain or branched chain C 2-6 alkenyl group, (c) an optionally substituted straight chain or branched chain C 2-6 alkynyl group, (d) Aryl, (e) Aromatic heterocycle, (f) Heterocycle, and (g) hydrogen; where the optional substituents in groups (a), (b) and (c) above are selected from: C 3-7 cycloalkyl, Aryl, Aromatic heterocycle, Heterocycle, OR 9 , NR 9 R 10 , S(O) p R 9 , OC(O)R 10 , CO 2 R 9 , CONR 9 R 10 , SO 2 NR 9 R 10 , halo and NHSO 2 R 9 , and where p is 0, 1 or 2; R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and straight chain or branched chain C 1-6 alkyl optionally substituted by OR 9 or halo; R 9 and R 10 are each independently selected from hydrogen and straight chain or branched chain C 1-6 alkyl; Aryl is a 6-14 membered aromatic monocyclic or fused polycyclic carbocyclic group optionally substituted with one or more groups selected from R 11, halo, OR 12 , NR 12 R 13 , NR 12 CO 2 R 11 , CO 2 R 12 , NR 12 SO 2 R 11 , CN, haloalkyl, O(haloalkyl), SR 12 , S(O)R 11 , SO 2 R 11 , OC(O)R 12 , SO 2 NR 12 R 13 and C(O)NR 12 R 13 , where R 11 is straight chain or branched chain C 1-6 alkyl and R 12 and R 13 are each independently selected from hydrogen and straight chain or branched chain C 1-6 alkyl; Aromatic heterocycle is a 5 to 7 membered aromatic ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being optionally substituted with one or more groups selected from OR 12 , NR 12 R 13 , CO 2 R 12 , NR 12 CO 2 R 11 , R 11 , halo, CN, haloalkyl, O(haloalkyl), SR 12 , S(O)R 11 , SO 2 R 11 , OC(O)R 12 , NR 12 SO 2 R 11 , SO 2 NR 12 R 13 and C(O)NR 12 R 13 ; and Heterocycle is a 3 to 8 membered ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, said ring further being optionally substituted with one or more groups selected from OR 12 , NR 12 R 13 , CO 2 R 12 , NR 12 CO 2 R 13 , R 11 , halo, CN, haloalkyl, O(haloalkyl), SR 12 , S(O)R 11 , SO 2 R 11 , OC(O)R 12 , NR 12 SO 2 R 11 , SO 2 NR 12 R 13 and C(O)NR 12 R 13 , or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of said medicament or said tautomer wherein said medicament is for the treatment of a condition selected from thrombotic conditions, atherosclerosis, adhesions, dermal scarring, fibrotic conditions and inflammatory diseases.